Language
English
Publication Date
12-1-2022
Journal
Current Opinion in Organ Transplantation
DOI
10.1097/MOT.0000000000001029
PMID
36222821
PMCID
PMC9613597
PubMedCentral® Posted Date
12-1-2023
PubMedCentral® Full Text Version
Author MSS
Abstract
Purpose of review: Multidrug-resistant organisms (MDROs) are prevalent in transplant recipients and associated with poor outcomes. We review recent cases of phage therapy used to treat recalcitrant infections in transplant recipients and explore the future role of such therapy in this setting.
Recent findings: Individual case reports and small case series suggest possible efficacy of phage therapy for the treatment of MDRO infections in pre and posttransplant patients. Importantly, there have been no serious safety concerns in the reported cases that we reviewed. There are no applicable randomized controlled trials (RCTs) to better guide phage therapy at this time.
Summary: Given the safety and possibility of successful salvage therapy of MDRO infections using bacteriophages, it is reasonable to pursue phage therapy for difficult-to-treat infections on a compassionate use basis, but RCT data are critically needed to better inform management.
Keywords
Humans, Phage Therapy, Drug Resistance, Multiple, Bacterial, Transplant Recipients, Anti-Bacterial Agents, Bacterial Infections
Published Open-Access
yes
Recommended Citation
, "Role of Bacteriophage Therapy for Resistant Infections in Transplant Recipients" (2022). Faculty, Staff and Students Publications. 4681.
https://digitalcommons.library.tmc.edu/baylor_docs/4681